Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis

Arthritis and Rheumatism

Volumn 54, Issue 11, 2006, Pages 3655-3660

  Kissin, Eugene Y ^a,b   Merkel, Peter A ^a   Lafyatis, Robert ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYCLOPHOSPHAMIDE; HYALIN;

ADULT; AGED; ARTICLE; CELL FUNCTION; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DUROMETRY; EVALUATION; FEMALE; FOREARM; HUMAN; HUMAN TISSUE; HYALINE DEGENERATION; MALE; MEASUREMENT; MYOFIBROBLAST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONTENT; QUANTITATIVE ANALYSIS; SKIN BIOPSY; SKIN DISEASE; SKIN FIBROSIS; SKINFOLD THICKNESS; STATISTICAL ANALYSIS; SYSTEMIC SCLEROSIS;

ADULT; BIOLOGICAL MARKERS; BIOPSY; COLLAGEN; DERMIS; FEMALE; FIBROBLASTS; HUMANS; HYALIN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SCLERODERMA, SYSTEMIC;

EID: 33750952919     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22186     Document Type: Article

References (19)

1. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990;33:1256-63.
2. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445-54.
3. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35.
4. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22:130-40.
5. Sappino AP, Masouye I, Saurat JH, Gabbiani G. Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol 1990;137:585-91.
6. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
7. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003;30:1630-47.
8. Kissin EY, Schiller AM, Gelbard RB, et al. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006;55:603-9.
9. Falanga V, Bucalo B. Use of a durometer to assess skin hardness. J Am Acad Dermatol 1993;29:47-51.
10. Davenport WD. A rapid trichrome staining procedure for the identification of tissue types. Histochem J 1979;11:367-70.
11. Schmitt-Graff A, Kruger S, Bochard F, Gabbiani G, Denk H. Modulation of α smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol 1991;138:1233-42.
12. Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 2005;7: R1113-23.
13. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995;105:280-4.
14. Kissin E, Korn JH. Apoptosis and myofibroblasts in the pathogenesis of systemic sclerosis. Curr Rheumatol Rep 2002;4:129-35.
15. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000;43:2230-9.
16. Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995;146:56-66.
17. Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003;22:289-94.
18. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001;60:577-84.
19. Clements P, Furst DE, Silver RM, Tashkin DP, Roth MD, Goldin J, et al. The Scleroderma Lung Study (SLS) shows the beneficial effects of cyclophosphamide (CYC) over placebo (PL) in systemic sclerosis (SSc) patients with active alveolitis. Arthritis Rheum 2005;52 Suppl 9:S257.